Like us on Facebook!

Eosinophilic Esophagitis Trial

Eosiniphilic esophagitis (EoE) is defined as “a chronic, immune/antigen-mediated esophageal disease characterized clinically by symptoms related to esophageal dysfunction and histologically by eosinophil predominant inflammation”( Liacouras et al., 2011).

EoE is considered a swallowing disorder. Clinical symptoms of EoE often vary by age, GWR upper GI Adam

  • Infants and toddlers present with feeding difficulties
  • School-aged children are more likely to present with vomiting or pain
  • Adolescents and adults present with dysphagia and food impaction.

When these symptoms are present, the diagnosis is confirmed by finding eosinophilic inflammation of 15 eosinophils/high-powered field (HPF) on at least 1 esophageal biopsy and when other causes such as proton pump inhibitor (PPI)- responsive esophageal eosinophilia are excluded (Dellon et al., 2014a: Furuta et al., 2007).

The standards of care are diet therapies and off-label use of glucocorticosteroids. Esophageal dilation is used to temporarily relieve symptoms but does not address underlying inflammation. Given the clinical outcomes associated with EoE , including severe dysphagia, esophageal stricture, food impaction, and esophageal perforation (Hirano and Aceves, 2014; Liacouras et al., 2011) and the fact that there are currently no FDA approved treatments, there is a clear unmet medical need for a novel treatment for this disease.

Click to learn more about Eosinophilic Esophagitis


We are currently conducting a clinical trial for patients with Eosinophilic Esophagitis.

To be included, participants must:

  • Be between the ages of 18-55
  • Suffer from any of these: eating problems, abdominal pain, heartburn, trouble swallowing, vomiting, or food impaction
  • Have taken medication for heartburn and has not helped

If you meet these criteria, then you may be eligible to participate in our study.

Click here for clinical trials details (

Share This: